FDA approves Roche's cobas pro i 601 platform with Ionify Gabapentin assay
+1 new source since this summary was written
Roche Diagnostics announced that the U.S. Food and Drug Administration has approved its cobas pro i 601 system together with the Ionify Gabapentin test. The clearance adds a therapeutic‑drug‑monitoring assay to Roche’s mass‑spectrometry portfolio for routine clinical labs. Roche will use an FDA‑authorized Predetermined Change Control Plan to introduce up to 22 additional Ionify assays in the future. The company did not provide revenue forecasts for the new platform.
Why it matters
The approval expands Roche’s diagnostic menu into therapeutic drug monitoring, potentially increasing assay sales as laboratories adopt the automated mass‑spectrometry workflow. The authorized change‑control plan gives Roche a regulatory pathway to add many more assays without separate submissions, which could boost future revenue streams.
Key facts
- 1The FDA granted approval for the cobas pro i 601 platform with the Ionify Gabapentin assay. prnewswire.com
- 2The authorization adds a therapeutic‑drug‑monitoring application to Roche’s U.S. mass‑spectrometry menu, which already includes 25‑Hydroxy Vitamin D total and steroid hormone tests such as estradiol and 17‑Hydroxyprogesterone. prnewswire.com
- 3Roche may add up to 22 additional Ionify assays under an authorized Predetermined Change Control Plan, pending regulatory requirements. prnewswire.com
- 4Dan Malarek, President and CEO of Roche Diagnostics North America, said the automation will make complex mass‑spectrometry testing more accessible to routine laboratories. finance.yahoo.com
- 5Roche did not disclose any financial projections or expected revenue contribution from the newly approved platform. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.